By Cecilia Butini

Merck KGaA said Monday that it plans to introduce one new healthcare product every one and a half years as it seeks to double research and development in oncology, neurology and immunology.

The German healthcare and technology company said more than 50% of future launches will result from co-development partnerships with external companies and in-licensing of assets.

The next wave of launches are expected to come from phase-3 trials of head-and-neck cancer medicine xevinapant and evobrutinib, a potential treatment for relapsing multiple sclerosis, the company said.

Merck's expected new launches could be either for new drugs or for new uses of existing drugs, it said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

November 21, 2022 07:48 ET (12:48 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Merck KGaA (PK) Charts.